Raphael Pharmaceutical Changes Executive Offices to Israel

TL;DR

Raphael Pharma moved its HQ to Israel. No other news.

AI Summary

Raphael Pharmaceutical Inc. filed an 8-K on June 26, 2024, reporting a change in its principal executive offices to 4 Lui Paster, Tel Aviv-Jaffa, Israel, 6803605. The company, previously incorporated in Nevada, also updated its business and mailing addresses. This filing does not appear to contain any material financial or operational updates beyond the address change.

Why It Matters

A change in principal executive offices can indicate shifts in operational focus or management location, potentially impacting future strategic decisions and investor relations.

Risk Assessment

Risk Level: low — The filing primarily reports a change of address, which is a routine administrative update and does not inherently signal significant business risk.

Key Players & Entities

• Raphael Pharmaceutical Inc. (company) — Registrant
• June 26, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of Incorporation
• 4 Lui Paster Tel Aviv-Jaffa, Israel (address) — Principal Executive Offices
• 000-53002 (filing_id) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — r of authorized shares of common stock, $0.01 par value per share (the "Common Stock"

Filing Documents

• ea0208572-8k_raphael.htm (8-K) — 25KB
• ea020857201ex3-1_raphael.htm (EX-3.1) — 22KB
• 0001213900-24-056191.txt ( ) — 218KB
• raph-20240626.xsd (EX-101.SCH) — 3KB
• raph-20240626_lab.xml (EX-101.LAB) — 33KB
• raph-20240626_pre.xml (EX-101.PRE) — 22KB
• ea0208572-8k_raphael_htm.xml (XML) — 3KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amended and Restated Articles of Incorporation On June 26, 2024, Raphael Pharmaceutical Inc. (the "Company") filed its Amended and Restated Articles of Incorporation (the "Amended and Restated Articles of Incorporation") with the Secretary of State of the State of Nevada, pursuant to which the Company increased the number of authorized shares of common stock, $0.01 par value per share (the "Common Stock"), from 21,020,560 shares to 50,000,000 shares (the "The Authorized Capital Change"). The Authorized Capital Change took effect on June 26, 2024. The board of directors of the Company approved the Authorized Capital Change on May 9, 2024, and the holders of a majority of the Company's outstanding common stock approved the Authorized Capital Change on May 22, 2024. The foregoing description of the Amended and Restated Articles of Incorporation does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Articles of Incorporation, a copy of which is filed as Exhibit 3.1 hereto and incorporated by reference herein.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Articles of Incorporation of Raphael Pharmaceutical Inc. dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPHAEL PHARMACEUTICAL INC. Date: June 26, 2024 By: /s/ Guy Ofir Name: Guy Ofir Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR